RHEUMATOLOGIC MASKS IN CANCER PATIENTS

DOI: https://doi.org/10.29296/25877305-2023-10-12
Issue: 
10
Year: 
2023

M. Kashpanov(1); Professor I. Novikova(2), MD
1-Murmansk City Polyclinic Two
2-Northern State Medical University, Arkhangelsk

Paraneoplastic syndromes (PS) are a group of syndromes caused by the indirect effect of the tumor process on the metabolism, immunity and regulatory systems of the body and manifesting themselves at a distance from the tumor and its metastases. The relevance of PS research is undeniable due to the increasing prevalence of cancer. Early diagnosis and multidisciplinary approach contribute to timely prescription of therapy and a positive prognosis of the disease.
Keywords: 
clinical case
dermatomyositis
paraneoplastic syndrome.

References: 
  1. Рак. Информационный бюллетень. ВОЗ, 2012; №297 [Cancer. Fact sheets. WHO, 2012; №297 (in Russ.)].
  2. Ветчинников О.Н., Никольская И.Г., Синякова Л.А. Инфекция мочевыводящих путей при беременности: учебное пособие. М., 2016 [Vetchinnikov O.N., Nikol'skaya I.G., Sinyakova L.A. Infektsiya mochevyvodyashchikh putei pri beremennosti: uchebnoe posobie. M., 2016 (in Russ.)].
  3. Прокопенко Е.И., Никольская И.Г., Ватазин А.В. и др. Хроническая болезнь почек и беременность. М.: ГБУЗ МО МОНИКИ, 2013; 31 [Prokopenko E.I., Nikol'skaya I.G., Vatazin A.V. et al. Khronicheskaya bolezn' pochek i beremennost'. M.: GBUZ MO MONIKI, 2013; 31 (in Russ.)].
  4. Sigurgeirsson B., Lindelof B., Edhag O. et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992; 326 (6): 363–7. DOI: 10.1056/NEJM199202063260602
  5. Barnes B.E., Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med. 1976; 84 (1): 68–76. DOI: 10.7326/0003-4819-84-1-68
  6. Rai S.K., Choi H.K., Sayre E.C. et al. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology (Oxford). 2016; 55 (3): 461–9. DOI: 10.1093/rheumatology/kev336
  7. Mimori T., Imura Y., Nakashima R. et al. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007; 19 (6): 523–9. DOI: 10.1097/BOR.0b013e3282f01a8c
  8. Koenig M., Fritzler M.J., Targoff I.N. et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007; 9 (4): R78. DOI: 10.1186/ar2276
  9. Колядина И.В., Поддубная И.В. Современные возможности терапии HER2-положительного рака молочной железы (по материалам клинических исследований). Современная онкология. 2014; 4: 10–21 [Kolyadina I.V., Poddubnaya I.V. Modern possibilities of her2 positive breast cancer treatment (based on clinical trials). Journal of Modern Oncology. 2014; 4: 10–21. (in Russ.)].
  10. Hendren E., Vinik O., Faragalla H. et al. Breast cancer and dermatomyositis: a case study and literature review. Curr Oncol. 2017; 24 (5): e429–e433. DOI: 10.3747/co.24.3696